Preparation and Evaluation of Nano-vesicles of Brimonidine Tartrate as an Ocular Drug Delivery System
Prabhu P1★, Nitish Kumar R1, Koland M1, Harish NM1, Vijayanarayan K1, Dhondge G1, Charyulu RN1★ Corresponding author
- 1Department of Pharmaceutics, N.G.S.M. Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore, INDIA.
CORRESPONDENCE
Prabhu P
Department of Pharmaceutics, N.G.S.M. Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore, INDIA.
Volume 2, Issue 4 · pp. 356–361 · PUBLISHED · DOI: 10.4103/0975-1483.71623
ABSTRACT
The objective of the present investigation was to design a vesicular formulation of brimonidine tartrate and evaluate its ability to reduce the dosing frequency and improve the therapeutic efficacy of the drug. Nanovesicles of brimonidine tartrate were prepared by film hydration method. The prepared vesicles were evaluated for photomicroscopic characteristics, entrapment efficiency, in vitro, and ex-in vitro drug release and in vivo intraocular pressure (IOP) lowering activity. The methods employed for preparation of vesicles produced nano vesicles of acceptable shape and size. The in vitro, and ex-in vitro drug release studies showed that there was slow and prolonged release of the drug, which followed zero-order kinetics. The IOP-lowering activity of nano vesicles was determined and compared with that of pure drug solution and showed that the IOP-lowering action of nano-vesicles sustained for a longer period of time. Stability studies revealed that the vesicle formulations were stable at the temperature range of 2-8°C, with no change in shape and drug content. The results of the study indicate that it is possible to develop a safe and physiologically effective topical formulation that is also convenient for patients.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
P, P., R, N. K., M, K., NM, H., K, V., G, D., & RN, C. (). Preparation and Evaluation of Nano-vesicles of Brimonidine Tartrate as an Ocular Drug Delivery System. Journal of Young Pharmacists, 2(4), 356–361. https://doi.org/10.4103/0975-1483.71623